Cigna Healthcare introduced Embarc Benefit Protection in July 2020 to provide an affordable network solution for gene therapy drugs, aiming to increase access for patients and lower costs for clients. Embarc Benefit Protection also allows clients to share in a better-than-expected experience in the event of a surplus across the company's entire book of business. Your clients may be recieving an email that informs them of their enrollment with Embarc Benefit Protection and will receive their portion of the 2022 surplus, which operated at a surplus for the calendar year.
ASO clients recieved a notification on 3/23/2023, and the surplus will be distributed by March 31, 2023. Please see the attached flyer for more information and contact your Cigna Healthcare representative if you have any questions.